Stay updated with breaking news from Nasdaq Rare. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year price […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The business had […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its price objective increased by TD Cowen from $59.00 to $61.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on RARE. Wedbush reissued a neutral rating […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.73) per share for the quarter. Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company […]
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...